SEOUL, Dec. 21 (Korea Bizwire) — South Korean drugmaker maker Daewoong Pharmaceutical Co. aims to launch a treatment drug for the novel coronavirus early next year, the company’s chief said Monday. Foistar, an oral protease inhibitor, is currently undergoing phase two clinical trial on COVID-19 patients with mild symptoms. The company aims to release the [...]
SEOUL, Nov. 18 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s coronavirus treatment is likely to file for emergency authorization use from local drug authorities next month, the company’s chief said Wednesday. CT-P59, anti-COVID-19 monoclonal antibody treatment, is currently undergoing a phase two clinical trial locally after successfully completing a phase one clinical trial [...]
SEOUL, Nov. 11 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc.’s COVID-19 treatment kills the coronavirus within 4-5 days, effectively protecting patients with mild symptoms from developing a severe case, the company’s chief said Wednesday. Celltrion Group Chairman Seo Jung-jin said the first stage trial of CT-P59, anti-COVID-19 monoclonal antibody treatment, shortened the recovery [...]
SEOUL, Aug. 6 (Korea Bizwire) — A state-run research institute with a specialty in weapons development is now developing a cure for COVID-19. South Korea’s Agency for Defense Development (ADD) announced on Wednesday that it confirmed the effectiveness of its newly-developed COVID-19 siRNA gene therapy treatment after conducting animal tests. The new treatment is designed [...]
VANCOUVER, British Columbia, Aug. 5 (Korea Bizwire) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The countries participating in [...]